D-0391-2024 Class II Ongoing

Recalled by Eugia US LLC — East Windsor, NJ

FDA drug recall D-0391-2024 was initiated by Eugia US LLC on Feb 20, 2024 and is designated Class II. Reason for recall: Failed Impurities/Degradation Specifications: Out of specification for organic impurities The recall status is ongoing. Affected quantity: 43,920 vials.

Recall details

Product Type
Drugs
Report Date
Mar 27, 2024
Initiation Date
Feb 20, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
43,920 vials

Product description

Nicardipine Hydrochloride Injection, USP 25mg/mL (2.5 mg/mL) 10 mL vials, Distributed by: AuroMedics Pharma LLC 279 Princeton-Hightstown Rd. E. Windsor, NJ 08520, NDC 55150-183-11

Reason for recall

Failed Impurities/Degradation Specifications: Out of specification for organic impurities

Distribution pattern

Nationwide within the United States

Code information

Lot #: 3NC22019, Exp. Date 2/24

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0391-2024
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0391-2024. Report a data issue: hello@regdatalab.com.